3D Cell Culture Global Market – Forecast To 2024
1 EXECUTIVE SUMMARY 24
2 INTRODUCTION 29
- 2.1 KEY TAKEAWAYS 29
- 2.2 REPORT DESCRIPTION 29
- 2.3 MARKETS COVERED 31
- 2.4 STAKEHOLDERS 33
- 2.5 RESEARCH METHODOLOGY 33
- 2.5.1 MARKET SIZE ESTIMATION 35
- 2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 37
- 2.5.3 SECONDARY SOURCES 38
- 2.5.4 PRIMARY SOURCES 38
- 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 39
- 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 39
- 2.5.7 ASSUMPTIONS 40
3 MARKET ANALYSIS 41
- 3.1 INTRODUCTION 41
- 3.2 MARKET SEGMENTATION 42
- 3.3 FACTORS INFLUENCING MARKET 43
- 3.3.1 DRIVERS AND OPPORTUNITIES 43
- 3.3.1.1 Substantial R&D investments for 3D cell culture 43
- 3.3.1.2 Use of 3D cell culture models in drug discovery and research as an
alternative to animal testing 44
- 3.3.1.3 Emergence of microfluidic technology and bioprinting 45
- 3.3.1.4 Increasing focus on regenerative medicine 46
- 3.3.1 DRIVERS AND OPPORTUNITIES 43
- 3.3.2 RESTRAINTS AND THREATS 46
- 3.3.2.1 Lack of experienced and skilled professionals 46
- 3.3.2.2 Budget restriction for small and medium sized laboratories and lack of
consistency in 3D cell culture products 47
- 3.3.2.3 Stringent process controls for advanced handling capabilities 47
- 3.3.2.4 Ethical concern over use of animal sources 48
- 3.4.1 UNITED STATES 49
- 3.4.2 EUROPE 50
- 3.4.3 INDIA 51
- 3.4.4 JAPAN 52
- 3.5.1 INTRODUCTION 53
- 3.5.2 ORGAN-ON-CHIP 53
- 3.5.3 3D BIOPRINTING 54
- 3.5.4 SINGLE USE REACTORS 54
- 3.6.1 THREAT OF NEW ENTRANTS 56
- 3.6.2 THREAT OF SUBSTITUTES 56
- 3.6.3 BARGAINING POWER OF SUPPLIERS 57
- 3.6.4 BARGAINING POWER OF BUYERS 57
- 3.6.5 RIVALRY AMONG EXISTING COMPETITORS 58
- 3.7.1 RAW MATERIAL SUPPLIER: 59
- 3.7.2 PRODUCT MANUFACTURERS:- 60
- 3.7.3 3D CELL CULTURE PRODUCTS DISTRIBUTORS 60
- 3.7.4 END-USERS 60
4 3D CELL CULTURE GLOBAL MARKET, BY TECHNOLOGY 64
- 4.1 INTRODUCTION 64
- 4.2 SCAFFOLD BASED PLATFORMS 69
- 4.2.1 SCAFFOLDS 72
- 4.2.2 HYDROGELS 74
- 4.2.3 OTHERS 76
- 4.3 SCAFFOLD FREE PLATFORMS 77
- 4.3.1 HANG DROP METHOD 80
- 4.3.2 FORCED FLOATING 82
- 4.3.3 AGITATION BASED METHODS 83
- 4.3.4 MICROFLUIDICS 85
5 3D CELL CULTURE GLOBAL MARKET, BY PRODUCTS 88
- 5.1 INTRODUCTION 88
- 5.2 CELLS AND TISSUES 90
- 5.3 MEDIA, SERA AND REAGENTS 92
- 5.4 MICROPLATES AND OTHERS 95
- 5.5 ASSAY KITS 98
- 5.6 SCAFFOLDS 99
- 5.6.1 NATURAL SCAFFOLDS 104
- 5.6.2 SYNTHETIC SCAFFOLDS 112
- 5.6.3 HYBRID COMPOSITE 119
- 5.6.4 HYDROGELS 120
- 5.7 OTHERS 122
6 3D CELL CULTURE GLOBAL MARKET, BY APPLICATION 128
- 6.1 INTRODUCTION 128
- 6.2 BASIC RESEARCH 131
- 6.3 TOXICITY AND DRUG SAFETY SCREENING 133
- 6.4 TISSUE ENGINEERING 135
- 6.5 STEM CELL RESEARCH 136
- 6.6 DRUG DISCOVERY 138
- 6.7 CANCER RESEARCH 140
- 6.8 GENE THERAPY 142
7 3D CELL CULTURE GLOBAL MARKET, BY END-USERS 144
- 7.1 INTRODUCTION 144
- 7.2 ACADEMIC INSTITUTES 145
- 7.3 BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES 147
- 7.4 OTHERS 148
8 REGIONAL ANALYSIS 151
- 8.1 INTRODUCTION 151
- 8.2 NORTH AMERICA 153
- 8.2.1 U.S. 167
- 8.2.2 OTHERS 170
- 8.3 EUROPE 173
- 8.3.1 GERMANY 186
- 8.3.2 U.K. 188
- 8.3.3 FRANCE 190
- 8.3.4 OTHERS 192
- 8.4 ASIA-PACIFIC 196
- 8.4.1 CHINA 209
- 8.4.2 JAPAN 212
- 8.4.3 KOREA 215
- 8.4.4 OTHERS 217
- 8.5 REST OF THE WORLD 221
- 8.5.1 BRAZIL 233
- 8.5.2 REST OF LATIN AMERICA 237
- 8.5.3 MIDDLE EAST AND OTHERS 240
9 COMPETITIVE LANDSCAPE 243
- 9.1 INTRODUCTION 243
- 9.2 COLLABORATIONS & PARTNERSHIPS 245
- 9.3 NEW PRODUCT LAUNCHES 248
- 9.4 AGREEMENTS, EXPANTIONS & MERGERS 250
- 9.5 COMPANY MATRIX 253
10 MAJOR COMPANIES 257
- 10.1 BECKTON DICKENSON AND COMPANY 257
- 10.1.1 OVERVIEW 257
- 10.1.2 FINANCIALS 259
- 10.1.3 PRODUCT PORTFOLIO 262
- 10.1.4 KEY DEVELOPMENTS 263
- 10.1.5 BUSINESS STRATEGY 263
- 10.1.6 SWOT ANALYSIS 264
- 10.2 CORNING INCORPORATED 265
- 10.2.1 OVERVIEW 265
- 10.2.2 FINANCIALS 267
- 10.2.3 PRODUCT PORTFOLIO 270
- 10.2.4 KEY DEVELOPMENTS 271
- 10.2.5 BUSINESS STRATEGY 271
- 10.2.6 SWOT ANALYSIS 272
- 10.3 INSPHERO AG 273
- 10.3.1 OVERVIEW 273
- 10.3.2 FINANCIALS 274
- 10.3.3 PRODUCT PORTFOLIO 274
- 10.3.4 KEY DEVELOPMENTS 275
- 10.3.5 BUSINESS STRATEGY 276
- 10.3.6 SWOT ANALYSIS 277
- 10.4 JSR CORPORATION (ORGANOGENIX INC.) 278
- 10.4.1 OVERVIEW 278
- 10.4.2 FINANCIALS 279
- 10.4.3 PRODUCT PORTFOLIO 279
- 10.4.4 KEY DEVELOPMENTS 279
- 10.4.5 BUSINESS STRATEGY 280
- 10.4.6 SWOT ANALYSIS 281
- 10.5 KURARAY CO. LTD 282
- 10.5.1 OVERVIEW 282
- 10.5.2 FINANCIALS 284
- 10.5.3 PRODUCT PORTFOLIO 287
- 10.5.4 KEY DEVELOPMENTS 287
- 10.5.5 BUSINESS STRATEGY 287
- 10.5.6 SWOT ANALYSIS 288
- 10.6 LONZA GROUP 289
- 10.6.1 OVERVIEW 289
- 10.6.2 FINANCIALS 291
- 10.6.3 SERVICE PORTFOLIO 293
- 10.6.4 KEY DEVELOPMENTS 296
- 10.6.5 BUSINESS STRATEGY 296
- 10.6.6 SWOT ANALYSIS 297
- 10.7 MERCK KGAA 298
- 10.7.1 OVERVIEW 298
- 10.7.2 FINANCIALS 300
- 10.7.3 PRODUCT PORTFOLIO 302
- 10.7.4 KEY DEVELOPMENTS 303
- 10.7.5 BUSINESS STRATEGY 303
- 10.7.6 SWOT ANALYSIS 304
- 10.8 NANO 3D BIOSCIENCES, INC 305
- 10.8.1 OVERVIEW 305
- 10.8.2 FINANCIALS 306
- 10.8.3 PRODUCT PORTFOLIO 306
- 10.8.4 KEY DEVELOPMENTS 307
- 10.8.5 BUSINESS STRATEGY 307
- 10.8.6 SWOT ANALYSIS 308
- 10.9 ORGANOVO HOLDINGS INC. 309
- 10.9.1 OVERVIEW 309
- 10.9.2 FINANCIALS 310
- 10.9.3 PRODUCT PORTFOLIO 311
- 10.9.4 KEY DEVELOPMENTS 311
- 10.9.5 BUSINESS STRATEGY 311
- 10.9.6 SWOT ANALYSIS 313
- 10.10 THERMO FISHER SCIENTIFIC, INC 314
- 10.10.1 OVERVIEW 314
- 10.10.2 FINANCIALS 316
- 10.10.3 PRODUCT PORTFOLIO 318
- 10.10.4 KEY DEVELOPMENTS 320
- 10.10.5 BUSINESS STRATEGY 320
3D cell culture is the method of creating an artificial environment that allows the cells to grow and interact within 3D structures. According to IQ4I analysis, the 3D cell culture global market is expected to grow at double digit CAGR to reach $1,485.1 million by 2024. Substantial R&D investments, use of 3D cell culture models in drug discovery and research as alternative to animal testing, emergence of microfluidic technology and bioprinting and increasing focus on regenerative medicine are some of the driving factors for this industry. However, lack of experienced and skilled professionals, budget restrictions for small and medium sized laboratories, lack of consistency in 3D cell culture products, stringent process controls for handling capabilities and ethical concerns over the use of animal sources are hindering the market to grow.
3D cell culture global market is classified based on technology, products, application, end-users, and geography. Based on technology the 3D cell culture market can be divided into two segments i.e., Scaffold based approaches and Scaffold free approaches. The scaffold based approaches are further classified into scaffolds, hydrogels and others. The scaffold free approaches are classified as the hang drop method, forced floating, agitation based methods, and microfludics. Based on products the segment is further classified as cells and tissues, media, sera and reagents, microplates and others, assay kits, scaffolds, and others (bioreactors and incubators). The application segment can be classified as basic research, toxicity and drug screening, tissue engineering, stem cell research, drug discovery, gene therapy and cancer research. The end-users segment can be classified as academic institutes, biotechnology and pharmaceutical industries and others.
Based on geography 3D cell culture global market is classified as North America, Europe, APAC and Rest of the world. North America accounts for the highest market share of 46.2% followed by Europe. However, Asian countries especially China and Japan are the fastest growing regions with its growing demand for 3D cell culture products.
Major players in 3D cell culture global market include.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Others
• Europe
o Germany
o U.K.
o France
o Others
• Asia-Pacific
o China
o Japan
o Korea
o Others
• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle-East and Others